July 28, 2023
Walking the walk
Quite frankly very little Dexcom does surprises us anymore. Unlike their main competitor Abbott, Dexcom isn’t about the bluster they are all about execution. They know Abbott is a strong competitor, but they are not scared of them and have actually become a better company because of them. Once again, the company exceeded expectations, raised guidance and showed everyone they aren’t folding.
We were particularly impressed with international results as Libre has long held a major advantage overseas. Those of us who have followed Dexcom since its inception understand that the company underestimated Libre when it first came . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
